CHICAGO, Jun 03, 2013 (BUSINESS WIRE) — — Rapid Onset of Clinical Activity …MarketWatch (press release)An investigator-sponsored Phase 1b, open-label, dose-escalation study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combina…
|
TG Therapeutics, Inc. Announces Presentation of Interim Results From Its Phase …
NASDAQ (press release) NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. ( TGTX ) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed and/or refractory Non-Hodgkin’s … |
|
TG Therapeutics , Inc . Announces Presentation of Interim Results From Its …
MarketWatch TG Therapeutics, Inc. (TGTX) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed and/or refractory Non-Hodgkin’s Lymphoma (NHL), presented at the American Society … |
|
TODAY ONLY! Vote Once from Anywhere to Win $17000 for MEandYou …
ProHealth 100,000 krone – that’s $17,000, £11,000 or 13,000 Euros – for MEandYou to fund Drs Fluge and Mella’s Rituximab trial in Norway! Click on the LINK , then on the circle besides MEandYou – and, of course share this with your friends! We are falling behind … |
Spectrum Pharmaceuticals Highlights Six Abstracts of Clinical Data at the 2013 …DailyFinanceThe ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined …
SPECTRUM PHARMACEUTICALS, INC. : Spectrum Pharmaceuticals Highlights …4-traders (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combin…
|
GSK eyes first-line use for leukaemia drug Arzerra
PMLiVE However, the product has been slow to gain traction in the CLL market, mainly because it has been reserved for use as a second-line therapy and has found it hard to displace Roche’s Rituxan/MabThera (rituximab) as the dominant therapy in the anti-CD20 … |
|
FDA’s CFS/ME Drug Development Workshop: Day Two: Afternoon Panels
ProHealth In his discussion of the rituximab study, Dr. Rowe pointed out that results need to be measured within the context of specific outcomes: cognitive improvement, activity, and functional measures. Simply asking patients how they feel compared with how … |
Drug Combo Helps Immune System Fight TumorsScience NowCombining a SIRPa protein (CV1 mono) and the cancer drug rituximab virtually wiped out tumors in mice after 29 days. Credit: Adapted From K. Weiskopf et al., Science (2013). To avoid being destroyed…
Drug Combo Helps Immune System Fight TumorsScience AAASCombining a SIRPa protein (CV1 mono) and the cancer drug rituximab virtually wiped out tumors in mice after 29 days. Credit: Adapted From K. Weiskopf et al., Science (2013). To avoid being destroy…